Innovative treatment for childhood brain tumors: Phase II trials of Tovorafenib is successful
- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
Innovative treatment for childhood brain tumors: Phase II trials of Tovorafenib is successful
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
Innovative treatment for childhood brain tumors: Phase II trials of Tovorafenib is successful, The overall response rate was 64%.
On June 13, Day One Biopharmaceuticals announced positive results from a pivotal Phase 2 clinical trial of its brain-penetrating, oral specific pan-RAF kinase inhibitor tovorafenib in patients with pediatric low-grade glioma (pLGG).
Among the first 22 evaluable patients, tovorafenib achieved an overall response rate (ORR) of 64%.
Top-line results from this trial are expected in the first quarter of next year, and if the results are positive, the company plans to submit a regulatory filing in the first half of next year.
Pediatric low-grade gliomas are the most common brain tumors in children, accounting for approximately 30–50% of all CNS tumors.
In pLGG patients, BRAF gene fusions are the most common cancer driver.
Currently approved BRAF inhibitors are only active against tumors with BRAF V600 mutations, have limited activity in brain tumors, and cannot be used in patients with BRAF fusions.
Tovorafenib is a highly specific pan-RAF kinase inhibitor that inhibits the growth of tumors harboring BRAF fusions or BRAF V600 mutations and is brain-penetrant.
It has received Breakthrough Therapy Designation and Rare Pediatric Disease Designation from the US FDA for the treatment of pLGG with activating RAF variants.
▲Introduction to Tovorafenib (Image source: Day One Biopharmaceuticals’ official website)
Trial data showed that in the first 22 patients evaluable for efficacy, tovorafenib achieved an ORR of 64%, including 14 patients with partial responses.
At the same time, 6 patients had stable disease, and the disease control rate was 91%.
All patients with stable disease also experienced tumor shrinkage, ranging from 19% to 34%. Responses were observed in both treatment-experienced patients with BRAF fusions or BRAF V600E mutations.
▲The efficacy data of Tovorafenib (Image source: Day One Biopharmaceuticals official website)
In terms of safety, tovorafenib was well tolerated based on data from 25 patients. Major adverse events were grade 1 or 2. Grade 3 or higher treatment-related adverse events occurred in 36% of patients.
“These preliminary studies show the potential of tovorafenib monotherapy for the treatment of relapsed/progressed pLGG,” said Samuel Blackman, MD, Co-Founder and Chief Medical Officer of Day One. “Our registrational study has completed enrollment of all patients and follow-up is ongoing. We expect to have top-line results from all participants in the first quarter of 2023. Based on these positive preliminary data, we plan to initiate a pivotal Phase 3 clinical trial evaluating tovorafenib as a first-line treatment for pLGG.”
References:
[1] Day One Announces Positive Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma. Retrieved June 13, 2022, from https://ir.dayonebio.com/news-releases/news -release-details/day-one-announces-positive-initial-data-pivotal-firefly-1-trial
Innovative treatment for childhood brain tumors: Phase II trials of Tovorafenib is successful, The overall response rate was 64%.
(source:internet, reference only)
Disclaimer of medicaltrend.org
